David Frederick Stern - Publications

1988- Pathology Yale University, New Haven, CT 
Receptors and Signal Transduction

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Haskins JW, Zhang S, Means RE, Kelleher JK, Cline GW, Canfrán-Duque A, Suárez Y, Stern DF. Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake. Science Signaling. 8: ra111. PMID 26535009 DOI: 10.1126/scisignal.aac5124  0.36
2015 Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget. PMID 26485762 DOI: 10.18632/oncotarget.6138  0.36
2015 Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Molecular Cancer Therapeutics. 14: 1680-92. PMID 25948295 DOI: 10.1158/1535-7163.MCT-15-0080  0.36
2015 Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z, Bosenberg MW, Stern DF. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell & Melanoma Research. 28: 417-30. PMID 25854919 DOI: 10.1111/pcmr.12376  0.36
2015 Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, et al. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Research. 75: 1399-412. PMID 25712345 DOI: 10.1158/0008-5472.CAN-14-2785  0.36
2014 Wali VB, Gilmore-Hebert M, Mamillapalli R, Haskins JW, Kurppa KJ, Elenius K, Booth CJ, Stern DF. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis. Breast Cancer Research : Bcr. 16: 501. PMID 25516216 DOI: 10.1186/s13058-014-0501-z  0.36
2014 Haskins JW, Nguyen DX, Stern DF. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Science Signaling. 7: ra116. PMID 25492965 DOI: 10.1126/scisignal.2005770  0.36
2014 Colavito SA, Zou MR, Yan Q, Nguyen DX, Stern DF. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. Breast Cancer Research : Bcr. 16: 444. PMID 25252859 DOI: 10.1186/s13058-014-0444-4  0.36
2014 Wali VB, Haskins JW, Gilmore-Hebert M, Platt JT, Liu Z, Stern DF. Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells. Molecular Cancer Research : McR. 12: 1140-55. PMID 24829397 DOI: 10.1158/1541-7786.MCR-13-0637  0.36
2013 Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF. Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. Plos One. 8: e79901. PMID 24278211 DOI: 10.1371/journal.pone.0079901  0.36
2013 Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Research. 73: 5053-65. PMID 23794705 DOI: 10.1158/0008-5472.CAN-12-3775  0.36
2013 Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discovery. 3: 52-67. PMID 23239741 DOI: 10.1158/2159-8290.CD-12-0408  0.36
2012 Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, ... ... Stern DF, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics. 44: 1006-14. PMID 22842228 DOI: 10.1038/ng.2359  0.36
2011 Wilson KA, Colavito SA, Schulz V, Wakefield PH, Sessa W, Tuck D, Stern DF. NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53. Molecular Cancer Research : McR. 9: 766-81. PMID 21551225 DOI: 10.1158/1541-7786.MCR-10-0317  0.36
2011 Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF. Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Molecular Cancer Research : McR. 9: 801-12. PMID 21521745 DOI: 10.1158/1541-7786.MCR-10-0512  0.36
2010 Mok J, Kim PM, Lam HY, Piccirillo S, Zhou X, Jeschke GR, Sheridan DL, Parker SA, Desai V, Jwa M, Cameroni E, Niu H, Good M, Remenyi A, Ma JL, ... ... Stern DF, et al. Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs. Science Signaling. 3: ra12. PMID 20159853 DOI: 10.1126/scisignal.2000482  0.36
2008 Jackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, Stern DF. ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Research : Bcr. 10: R96. PMID 19019207 DOI: 10.1186/bcr2198  0.36
2008 Wilson KA, Stern DF. NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway. Cell Cycle (Georgetown, Tex.). 7: 3584-94. PMID 19001859  0.36
2008 DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2364-72. PMID 18390970 DOI: 10.1200/JCO.2007.13.6580  0.36
2006 Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, Perry BN, Stern DF, Bowden GT, Liu A, Klein E, Kolodziejski PJ, Eissa NT, Hossain CF, Nagle DG. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar Journal of Investigative Dermatology. 126: 1396-1402. PMID 16614726 DOI: 10.1038/sj.jid.5700276  0.36
2005 Ptacek J, Devgan G, Michaud G, Zhu H, Zhu X, Fasolo J, Guo H, Jona G, Breitkreutz A, Sopko R, McCartney RR, Schmidt MC, Rachidi N, Lee SJ, Mah AS, ... ... Stern DF, et al. Global analysis of protein phosphorylation in yeast. Nature. 438: 679-84. PMID 16319894 DOI: 10.1038/nature04187  0.36
2005 Amin DN, Tuck D, Stern DF. Neuregulin-regulated gene expression in mammary carcinoma cells. Experimental Cell Research. 309: 12-23. PMID 15963498 DOI: 10.1016/j.yexcr.2005.04.034  0.64
2004 Amin DN, Perkins AS, Stern DF. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene. 23: 1428-38. PMID 14973552 DOI: 10.1038/sj.onc.1207257  0.64
2003 Lee SJ, Schwartz MF, Duong JK, Stern DF. Rad53 phosphorylation site clusters are important for Rad53 regulation and signaling. Molecular and Cellular Biology. 23: 6300-14. PMID 12917350 DOI: 10.1128/MCB.23.17.6300-6314.2003  0.36
2003 Schwartz MF, Lee SJ, Duong JK, Eminaga S, Stern DF. FHA domain-mediated DNA checkpoint regulation of Rad53. Cell Cycle (Georgetown, Tex.). 2: 384-96. PMID 12851493  0.36
2002 Digiovanna MP, Stern DF, Roussel RR. Production of antibodies that recognize specific tyrosine-phosphorylated peptides. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. Unit 11.6. PMID 18432869 DOI: 10.1002/0471142735.im0101s50  0.36
2002 DiGiovanna MP, Roussel RR, Stern DF. Production of antibodies that recognize specific tyrosine-phosphorylated peptides. Current Protocols in Cell Biology / Editorial Board, Juan S. Bonifacino ... [Et Al.]. Unit 16.6. PMID 18228399 DOI: 10.1002/0471143030.cb1606s13  0.36
2002 DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Research. 62: 6667-73. PMID 12438265  0.36
2002 Schwartz MF, Duong JK, Sun Z, Morrow JS, Pradhan D, Stern DF. Rad9 phosphorylation sites couple Rad53 to the Saccharomyces cerevisiae DNA damage checkpoint. Molecular Cell. 9: 1055-65. PMID 12049741 DOI: 10.1016/S1097-2765(02)00532-4  0.36
Show low-probability matches.